Bevacizumab biosimilar - Boehringer Ingelheim

Drug Profile

Bevacizumab biosimilar - Boehringer Ingelheim

Alternative Names: BI 695502

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Alliance for Clinical Trials in Oncology; Boehringer Ingelheim; National Cancer Institute (USA)
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • Phase II Brain metastases
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in New Zealand (IV, Infusion)
  • 01 Jun 2016 Phase-III clinical trials in Colorectal cancer (Metastatic disease, First-line therapy, Combination therapy) in Japan, Spain (IV) (NCT02776683)
  • 01 Apr 2016 Phase-II clinical trials in Brain metastases in USA (IV) (NCT02531659)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top